Adaptimmune Revenue and Competitors

Claim your profile

Abingdon, USA

Location

$399.5M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Adaptimmune's estimated annual revenue is currently $6.2M per year.(i)
  • Adaptimmune received $Undisclosed in venture funding in March 2017.
  • Adaptimmune's estimated revenue per employee is $10,779
  • Adaptimmune's total funding is $399.5M.
  • Adaptimmune's current valuation is $515.5M. (January 2022}

Employee Data

  • Adaptimmune has 578 Employees.(i)
  • Adaptimmune grew their employee count by 8% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$156.1M514-6%$145MN/A
#2
$14M90-37%$150MN/A
#3
$5.4M35-8%N/AN/A
#4
$5.3M34-35%N/AN/A
#5
$53.9M348-35%$75.1MN/A
#6
$7.9M51-11%N/AN/A
#7
$14.7M95-4%N/AN/A
#8
$36.1M233-30%$7MN/A
#9
$24.3M157-21%$20MN/A
#10
$4.8M31N/A$357.3MN/A

Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

$399.5M

Total Funding

578

Number of Employees

$6.2M

Revenue (est)

8%

Employee Growth %

$515.5M

Valuation

N/A

Accelerator

Adaptimmune News

2014-09-25 - Adaptimmune Raises $104m in Venture Capital

Adaptimmune, an Oxford, UK-based biotechnology company, raised $104m in venture capital. The round was led by New Enterprise Associates with participation from new investors OrbiMed Advisors, Wellington Management Company, Fidelity Biosciences, Foresite Capital Management, Ridgeback Capital Man ...

2015-05-07 - Bill and Melinda Gates Foundation putting $75M toward disease surveillance, Roche gets FDA approval for venetoclax (Morning Read)

LIFE SCIENCE Adaptimmune, a UK-based biotech using T-cell therapy to treat cancer and infectious disease, raised $191 million in its IPO. The company priced 11.3 million shares at the high end of the range ($17 per share) for a market cap of $1.3 billion, according to Fortune. But it wavered in ...

2021-02-13 - An­oth­er Keytru­da com­bo tops stan­dard of care in ad­vanced kid­ney can­cer, pos­ing new test for Bris­tol's I/O med

It makes sense to join forces with your partner’s owner. Japan’s Astellas Pharma is tying up with UK-based Adaptimmune Therapeutics in a deal worth up to $897.5 million to develop stem-cell-derived, off-the-shelf T-cell therapies. Since 2015, Adaptimmune has been collaborating with a Seattle ba ...

08/27/2019 - Adaptimmune and Noile-Immune Announce Agreement to ...

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation ...

08/29/2019 - EuroBiotech Report—Celgene-Immatics, AstraZeneca ...

Adaptimmune formed a preclinical research pact. InDex Pharmaceuticals presented phase 2b ulcerative colitis data. And more. — Nick Taylor

08/28/2019 - Adaptimmune and Noile-Immune to Develop SPEAR T-Cell ...

Adaptimmune Therapeutics (NASDAQ:ADAP) announced on Tuesday (August 27) it will be partnering with Japan-based Noile-Immune ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$135M600N/AN/A
#2
N/A778N/AN/A
#3
$222.8M7881%N/A
#4
$214.1M9385%N/A
#5
$253.5M12495%N/A

Adaptimmune Funding

DateAmountRoundLead InvestorsReference
2014-09-26$104.0MUndsiclosedMultipleArticle
2017-03-23$UndisclosedUndisclosedCitigroupArticle